PDC31

PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD) . PDC31 also enhances Ca2+-dependent large-conductance K+-channel in human myometrial cells[1][2].

Product Specifications

CAS Number

[634586-40-6]

Product Name Alternative

THG113.31; ILGHXDYK

UNSPSC

12352209

Target

Prostaglandin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/pdc31.html

Purity

99.92

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@H](C(N[C@@H](C(O)=O)CCCCN)=O)NC([C@@H](CC(O)=O)NC([C@@H](CCCNC(N)=O)NC([C@H](NC(CNC([C@@H](CC(C)C)NC([C@H](N)[C@H](C)CC)=O)=O)=O)CC2=CN=CN2)=O)=O)=O

Molecular Formula

C45H71N13O13

Molecular Weight

1002.12

References & Citations

[1]Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176 (8) :1059-1078. |[2]Doheny HC, et al. THG113.31, a specific PGF2alpha receptor antagonist, induces human myometrial relaxation and BKCa channel activation. Reprod Biol Endocrinol. 2007 Mar 16;5:10. |[3]Friel AM, et al. Specific PGF (2alpha) receptor (FP) antagonism and human uterine contractility in vitro. BJOG. 2005 Aug;112 (8) :1034-42. |[4]Böttcher B, et al. A first-in-human study of PDC31 (prostaglandin F2α receptor inhibitor) in primary dysmenorrhea. Hum Reprod. 2014 Nov;29 (11) :2465-73.